T he aim of the study was to investigate symptoms of hyperprolactinemia such as oligomenorrhea, amenorrhea, galactorrhea, and correlation between hyperprolactinemia and MRI of hypophysis in infertile women. Material and methods: During the 10 years period, we have studied 87 patients investigated for infertility causes and with hyperprolactinemia findings. In our patients we have controled the serum prolactin levels, performed MRI of hypophysis, evaluated menstrual cycle disturbances and galactorrhea. Patients were between 20-43 of age. Results: MRI of hypophysis confirmed prolactinoma (microadenoma) in 75,86% of our patients, while 24,14% had a normal MRI. Galactorrhea was demonstrated in 56,32% of patients. Oligomenorrhoea occured in 25,29%, and secondary amenorrhea in 14,94% of patients with hyperprolactinemia and infertility. The results show statistically significant difference in the average findings of serum prolactin levels on the day 8 and 21 of menstrual cycle in patients with or without microadenoma. Conclusions: Menstrual cycle disturbancies (oligomenorrhea and secondary amenorrhea) in patients with hyperprolactinemia and infertility occured in 40,33% of patients. We have noted statisctically significant correlation between the serum prolactin levels on the day 8 of menstrual cycle and the microadenoma size, which was not found on the 21 day of menstrual cycle.
INTRODUCTION
Hyperprolactinemia is a common endocrine disorder with gonadal dysfunction which typically presents as amenorrhea, oligomenorrhea,galactorrhea and infertility. When hyperprolactinemia is confirmed, a cause for the disorder needs to be sought. The most frequent cause of hyperprolactinemia is presence of micro or macroprolactinoma of hypophysis. The diagnosis of hyperprolactinemia and prolactinoma requires careful clinical evaluation, followed by laboratory tests and MRI of hypophysis.
By definition, prolactinomas express and secret prolactin, are mostly benign and are classified as microadenomas with a size of less than 10 mm in diameter or macroadenomas if greater than 10 mm in diameter (1) .
These pituitary tumors may produce an excessive amount of prolactin or disrupt the normal delivery of dopamine from the hypothalamus to the hypophysis. Prolactin secretion from the hypophysis is inhibited by dopamine released from neurones in the hypothalamus. Prolactin is mainly a lactogenic hormone but has other actions (2) .
Hyperprolactinemia causes infertility, but the mechanisms involved are not well known. The main known mechanisms is that prolactin regulates pulsatile secretion of GnRH, which results in the suppression of luteinising hormone secretion and hypoestrogenic status.
High serum prolactin can disturb follicular maturation and corpus luteum function (3) .
Hyperprolactinemia can cause luteal phase defect, which is one of the reasons of infertility.
Studies have shown that in a subgroup of asymptomatic patients the serum contains mainly high molecular weight form (big prolactin) which has a low bioactivity, called macroprolactinemia (3) . Identification of macroprolactinaemia is important to prevent unnecessary examinations and inappropriate treatment.
In the pathophysiology of macroprolactinemia it seems that pituitary prolactin has antigenicity, leading to the production of anti-prolactin auto antibodies, and these antibodies reduce prolactin bioactivity and delay prolactin clearance (4).
MATeRIAL AND MeTHODS
During the 10 years period, we have evaluated 87 patients whom were investigated for infertility causes and were with hyperprolactinemia findings. Patients were between 20-43 of age. Out of 87 patients, 32 were age of 20-30, 47 were age of 31-40, and 8 of them were age of 41-43. In our patients we have controlled serum prolactin levels on the day 8 and 21 of menstrual cycle, and performed a MRI of hypophysis.
We have compared the serum prolactin level and MRI of hypophysis fi ndings, and evaluated incidence and size of prolactinoma. Furthermore, we evaluated incidence of menstrual cycle disturbances (oligomenorrhea and secondary amenorrhea) and frequency of galactorrhea in those infertile patients with hyperprolactinemia.
ReSULTS
Analysis of age groups of patients included in this study showed that out of the total number of 87 patients (100%), 32 (36.78%) were in the age group of 20-30, 47 (54.02%) were in the age group of 31-40, while 8 (9.20%) were in the age group of 41-43. Chi-square test showed a statistically signifi cant diff erence in the number of patients by age groups, χ2=26.69, df=2, p<0.05 (Table 1) .
Of the total number of patients included in this study, 21 (24.14%) had normal MRI of the hypophysis, and in 66 (75.86%) of the patients MRI showed the presence of the hypophysis microadenomas, whereas MRI showed no presence of macroadenoma in any of the patients. Chi-square test confi rmed that there is a statistically signifi cant diff erence in the frequency of types of MRI of hypophysis fi ndings, and that microadenoma dominates in the study group, χ2=78,414, df=2, p <0.05 ( Figure 1) .
By analyzing the frequency of galactorrhea in patients with hyperprolactinemia and infertility, we have registered a positive fi nding in 49 (56.32%) patients and negative in 38 (43.68%). Chi-square test showed that there was no statistically signifi cant diff erence in the number of patients with positive and negative fi ndings of galactorrhea, χ2= 1.39, df=1, p = 0238 ( Figure 2 ).
In our study group 52 (59.77%) patients had a regular menstrual cycle, 22 (25.29%) had oligomenorrhea whereas secondary amenorrhea occurred in 13 (14.94%) patients. Th ere was a statistically signifi cant diff erence in the frequency of the normal menstrual cycle and menstrual cycle disorders, and the majority of patients had normal menstrual cycle, χ2=28.75, df=2, p<0.05 ( Figure 3) .
Th e average value of prolactin levels on the day 8 of menstrual cycle in patients with microadenoma was 1024.21±695.74µIU/ml (609-4881), and 889.26±254.72µIU/ml (608-1604) in patients without microadenoma. Th e analysis of the average levels of prolactin on the day 21 of menstrual cycle found that in patients with microadenoma values were 1121.97±418.02µIU/ ml (590-2835), and 1013.13±612.69µIU/ ml (597-2945) in patients without microadenoma. ANOVA test showed that there was a statistically signifi cant difference in mean values of prolactin levels on the day 8 and 21 of the cycle in patients with or without microadenoma ( Figure 4) .
Pearson Correlation showed that the value of prolactin levels at the day 8 of menstrual cycle is in a positive statistically signifi cant correlation with the size of the microadenoma (rho=0289, p= 0.036), but no evidence of correlation of prolactin levels at the day 21 of menstrual cycle and microadenoma size ( Table 2) .
It suggests that in infertile women with hyperprolactinemia there is a correlation between serum prolactin level at the day 8 of menstrual cycle and microadenoma size. None of the patients had bone destruction or neurological disorders caused by the pressure of the microadenoma on chiasma optica.
DISCUSSION
A number of factors can cause hyperprolactinemia but the most frequent pathologic cause is a prolactin secreting tumor of hypophisis, called prolactinoma.
Prolactinoma accounts for approximately 40% of all pituitary adenomas and is an important cause of hypogonadism and infertility (5) .
Th e vast majority (95%) of prolactinoma in women are microadenomas, which present with the clinical manifestations of hyperprolactinemia and rarely lead to hypopituitarism or neurologic dysfunction (6) . Tumor size correlated with the serum prolactin level, and there was a statistically significant association between the tumor size and the prolactin level, but some macroadenomas were detected in women 
Figure 2. MRI of hypophysis findings in patients with hyperprolactinemia
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Clinical symptoms are less frequent in macroprolactinemic patients, they could not be differentiated from true hyperprolactinemic patients, on the basis of clinical features alone (4) . On the basis of these findings, pituitary imaging should be obtained to identify pituitary tumors in all patients with persistently elevated prolactin levels (7) .
Most patients with idiopathic hyperprolactinemia may have radiologically undetected microprolactinomas, but some may present other causes of hyperprolactinemia described as macroprolactinema (4). In our study, in 24,14% of cases MRI of hypophysis did not diagnosed prolactinoma.
Macroprolactinemia can be considered a benign condition with low incidence of clinical symptoms and therefore hormonal and imaging investigations as well as medical or surgical treatment and prolonged follow-up not necessary (4) .
The prevalence of hyperprolactinemia is difficult to establish as not all sufferers are symptomatic or concerned by their symptoms and may remain undiagnosed (8) . In the higher number of cases hyperprolactinemia in women present with clinical manifestations of galactorrhea or amenorrhea, a change in the menses either in the amount or in regularity and infertility.
Galactorrhea was the most common presenting symptom occurring in 85% cases followed by amenorrhea in 68,9%, both amenorrhea and galactorrhea were seen in 45,4% patients (9). In our study there were 49( 56,32%) patients with galactorrhea, 13(14,94%) with secondary amenorrhea and 22 (25,29%) with oligomenorrhea. About 10-40% of women with hyperprolactinemia presents with secondary amenorrhea (2) . Galactorrhea is commonly caused by hyperprolactinemia, especially when it is associated with amenorrhea (10) .
For women of childbearing age, occurrence of galactorrhea, menstrual cycle disorders and infertility is specific at a time when prolactinoma is less than 10 mm, so that prolactinoma in the majority of cases is diagnosed as microadenoma and confirmed with MRI of the hypophysis.
Clinical presentation and consequences of hyperprolactinemia and prolactinoma will differ in the specific stages of reproductive life and require an adequate lifetime-dependent diagnostic and therapeutic approach (11).
CONCLUSION
In our patients we found a statistically significant correlation between serum prolactin levels at the day 8 of the menstrual cycle and the size of prolactinomas (microadenomas), indicating that the value of the prolactin level in hyperprolactinemia suggests microadenoma size, which was not proven for the day 21 of the cycle. Microadenoma was diagnosed in 75.86% of cases, and a normal MRI of the hypophysis in 24.14% of cases.
Galactorrhea was present in 56.32% of patients pointing to some hyperprolactinemia and that requires proper diagnosis. Secondary amenorrhea was present in 14.94%, and oligomenorrhea in 25.29% of our patients.
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